Universal Sarbeco coronavirus vaccine proves safe in first human trial

▤ Summary

A University of Cambridge spin-out, DIOSynVax, reported that its universal Sarbeco coronavirus vaccine passed first-in-human safety testing. The Phase I trial in 39 healthy volunteers found no significant side effects and showed immune responses against SARS-CoV-2, SARS, and related bat coronaviruses. The team used machine learning to design the vaccine antigen and delivered it as a DNA vaccine through a needle-free jet system. The next step is a larger Phase 2 trial to confirm broader immune response and advance the candidate toward public use.

▦ Linked Companies